Probiotics in the Treatment of Inflammatory Bowel Diseases
- 27 July 2024
- book chapter
- Published by Springer Nature
- Vol. 1449, 135-142
Abstract
Inflammatory bowel diseases (IBD) are chronic, incurable inflammatory condition of the gut. They comprise Crohn’s disease and ulcerative colitis. Crohn’s disease (CD) may affect any tract of the gastrointestinal (GI) tract and is a transmural inflammatory condition; ulcerative colitis (UC), on the other hand, is limited to the mucosal layer of the rectum and colon. Treatment options available for both IBD are notoriously loaded with potentially serious side effects and risks. Although the pathogenesis of IBD involves a complex interaction between genetic, environmental, microbial and immunological factors, there is evidence that the interplay between the microbiota and the GI mucosa has a preponderant role. It is therefore no surprise that in recent years, a growing interest for effective and safer alternatives has focused on the potential role of prebiotics and—especially—probiotics. The mechanisms of action underlying the potential benefits of probiotics in IBD have been largely and quite extensively investigated in vitro and in vivo experiments. In terms of clinical evidence, the results of trials in the induction of remission of active CD or the maintenance of its remission with probiotics have been so far largely disappointing, to the point that their use in this disease cannot be at present recommended. On the contrary, for the treatment as well as for maintenance therapy of UC, there is clinical evidence of efficacy for some specific strains or multi-strain preparations. It is evident that this is a rapidly evolving and promising field; more data are very likely to yield a better understanding on what strains and in what doses should be used in different specific clinical settings, as we expect new and exciting developments of precision and even personalized therapy by the fast-growing field of probiogenomics.Keywords
This publication has 41 references indexed in Scilit:
- Low diversity gut microbiota dysbiosis: drivers, functional implications and recoveryCurrent Opinion in Microbiology, 2018
- Current Evidence for the Management of Inflammatory Bowel Diseases Using Fecal Microbiota TransplantationCurrent Infectious Disease Reports, 2018
- Probiotics in Inflammatory Bowel DiseaseGastroenterology Clinics of North America, 2017
- Probiotics are a good choice in remission of inflammatory bowel diseases: A meta analysis and systematic reviewJournal of Cellular Physiology, 2017
- Age-related differences in presentation and course of inflammatory bowel disease: an update on the population-based literatureJournal of Crohn's and Colitis, 2014
- Complete genome sequence of the Gram-negative probiotic Escherichia coli strain Nissle 1917Journal of Biotechnology, 2014
- Mo1227 Ciprofloxacin and Probiotic Escherichia coli Nissle As Add-on Treatment in Active Ulcerative Colitis; a Double-Blinded Randomized Placebo Controlled Clinical TrialGastroenterology, 2014
- Saccharomyces boulardii Does Not Prevent Relapse of Crohn's DiseaseClinical Gastroenterology and Hepatology, 2013
- Probiotic preparation VSL#3 induces remission in children with mild to moderate acute ulcerative colitis: A pilot studyInflammatory Bowel Diseases, 2009
- Saccharomyces boulardii in Maintenance Treatment of Crohn’s DiseaseDigestive Diseases and Sciences, 2000